Uniqure (NASDAQ:QURE) Stock Rating Lowered by BidaskClub

Share on StockTwits

Uniqure (NASDAQ:QURE) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday, BidAskClub reports.

Several other research firms also recently weighed in on QURE. HC Wainwright set a $73.00 price target on Uniqure and gave the stock a “buy” rating in a research note on Monday, July 8th. Cantor Fitzgerald increased their price target on Cerner from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, July 8th. Zacks Investment Research upgraded SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Friday, July 5th. Piper Jaffray Companies set a $80.00 price target on Canopy Growth and gave the stock a “buy” rating in a research note on Friday, April 12th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a research note on Tuesday, June 11th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $78.18.

Shares of Uniqure stock opened at $70.32 on Friday. Uniqure has a 1 year low of $21.98 and a 1 year high of $82.49. The company’s fifty day simple moving average is $71.87. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38.

Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts expect that Uniqure will post -3 earnings per share for the current fiscal year.

In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $77.45, for a total value of $619,600.00. Following the completion of the transaction, the chief executive officer now owns 409,407 shares in the company, valued at approximately $31,708,572.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the transaction, the insider now owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. Insiders have sold a total of 23,546 shares of company stock valued at $1,556,820 in the last quarter. 2.91% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Xact Kapitalforvaltning AB purchased a new position in Uniqure in the 2nd quarter worth approximately $328,000. First Citizens Bank & Trust Co. purchased a new position in Uniqure in the 2nd quarter worth approximately $211,000. Sanders Morris Harris LLC purchased a new position in Uniqure in the 2nd quarter worth approximately $3,084,000. FMR LLC increased its stake in Uniqure by 0.8% in the 1st quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock worth $220,036,000 after purchasing an additional 29,629 shares during the period. Finally, Redmile Group LLC increased its stake in Uniqure by 0.3% in the 1st quarter. Redmile Group LLC now owns 1,307,522 shares of the biotechnology company’s stock worth $77,994,000 after purchasing an additional 4,100 shares during the period. Institutional investors and hedge funds own 60.10% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.